Blinatumomab consolidation for adults with B‑cell acute lymphoblastic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter registry that will collect both retrospective and prospective clinical data on adults with B‑cell acute lymphoblastic leukemia who receive blinatumomab during consolidation. Data entry and surveys will be managed through REDCap, a secure web application hosted by the Clinical & Translational Science Institute. The registry focuses on real‑world outcomes, including remission durability, relapse, minimal residual disease status, and safety/tolerability outside of controlled trials. Enrollment criteria specify adults aged 18 or older diagnosed on or after December 1, 2023, and exclude patients who received blinatumomab within an interventional clinical trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2022 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients

Exclusion Criteria:

* N/A

Where it's running

• Mayo Clinic Cancer Center
  Jacksonville, Florida, United States Recruiting
• Northwestern University
  Chicago, Illinois, United States Recruiting
• The University of Chicago
  Chicago, Illinois, United States Recruiting
• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting
• Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Study coordinator: Arielle Baim
• Email: abaim@mcw.edu
• Phone: 4148058745

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vaccine protection after blinatumomab in children with B-ALL

  This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.

  Recruiting at 2 sites Arkansas Children's Hospital Research Institute · Little Rock, Arkansas and 1 other locations · NCT07422337

• Blinatumomab plus low-dose donor cells after transplant for high-risk B-ALL

  This small, early-phase study tests whether giving blinatumomab with low-dose donor lymphocytes after allogeneic transplant is safe and helps long-term survival for people with high-risk B-ALL.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07677878

• LP-118 in combination with standard therapy for newly diagnosed Ph+ ALL

  This study tests whether adding LP-118 to the standard therapy for adults with Philadelphia chromosome–positive ALL is safe and useful.

  Recruiting at 2 sites Phase 1 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT07614022

• MK-1045 versus blinatumomab for relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia

  This trial will test whether MK-1045 helps people with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia more than the standard immunotherapy blinatumomab.

  Recruiting at 30 sites Phase 2/3 Merck Sharp & Dohme LLC · Toronto, Ontario and 29 other locations · NCT07570173

• Immunotherapy-based treatment for children with relapsed B-cell ALL (IntReALL BCP 2020)

  This study tests whether targeted immunotherapies like inotuzumab ozogamicin and blinatumomab can replace traditional chemotherapy to help children with relapsed precursor B-cell ALL.

  Recruiting at 9 sites Phase 3 Charite University, Berlin, Germany · Vienna and 20 other locations · NCT07476729

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.